Dr. Weiss is the Ephraim P. Engleman Distinguished Professor of Rheumatology in the Department of Medicine at the University of California, San Francisco, where he has been on the faculty since 1985. He served as Division Chief of Rheumatology at UCSF from 1988-2011. He has been an Investigator of the Howard Hughes Medical Institute since 1985.

Dr. Weiss is a leader in the field of signal transduction in the immune system, focusing on the roles of tyrosine kinases and phosphatases in regulating lymphocyte activation. He is interested in how abnormalities in tyrosine phosphorylation pathways can lead to immunologically-mediated diseases. He has coauthored more than 250 peer-reviewed original research publications and more than 80 reviews. Dr. Weiss received the William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute, the Lee C. Howley Prize from the Arthritis Foundation, the Distinguished Investigator Award from the American College of Rheumatology, and the Meritorious Career Award from the American Association of Immunologists (AAI) and the Huang Foundation. He is also a recipient of the Lifetime Achievement Award from the AAI. He is a member of the National Academy of Sciences, National Academy of Medicine, American Academy of Arts and Sciences, and the American Academy of Microbiology.

Previously Jasper’s acting CMO, Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals. Previously Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharmacyclics, and as a Clinical Scientist at Genentech where he was involved in the early development of omalizumab and bevacizumab. Dr. Adelman has also led the development of other therapies for celiac disease and food allergy. Dr. Adelman began his career as an Assistant Professor of Clinical Medicine in the Division of Allergy and Immunology at the University of California, San Francisco, School of Medicine, where he was also Director of Clinical Allergy and Immunology. He is also currently an Adjunct Professor of Medicine at UCSF, where he has taught and practiced at for more than 34 years, remaining on the faculty upon entering industry. He has also served on the editorial boards of the Journal of Clinical Immunology and Clinical Immunology, and as a clinical advisor to multiple biopharmaceutical companies. Dr. Adelman holds a bachelor’s degree in biology from the University of California, Berkeley, and earned his M.D. from the University of California, Davis.

Dr. Metcalfe is a Fellow of the American Academy of Allergy, Asthma, and Immunology and a member of the Association of American Physicians, Collegium Internationale Allergologicum, and American Clinical and Climatological Association.  Dr. Metcalfe received his M.D. at the University of Tennessee and an M.S. in microbiology at the University of Michigan, where he also did a residency in internal medicine. Dr. Metcalfe then trained in allergy and immunology during a fellowship at NIAID, followed by training in rheumatology while a Fellow in Immunology at the Robert Brigham Hospital in Boston. In 1995, he was appointed as the first Chief of the newly created Laboratory of Allergic Diseases at NIAID, a position he continued for 22 years until stepping down as Laboratory Chief in 2017. He is a past president of the American Academy of Allergy, Asthma, and Immunology, and a past chair of the American Board of Allergy and Immunology. Dr. Metcalfe is a recipient of numerous awards including the Commendation, Outstanding Service and Meritorious Service Medals of the USPHS, an Outstanding Alumnus Award from University of Tennessee College of Medicine Alumni, the Distinguished Scientist Award from the Association the American Academy of Allergy and Asthma and Immunology, the Distinguished Scientist Award from the World Allergy Organization, the Lifetime Mentorship Award from the AAAAI and the ECNM Researcher of the Year.

Dr. Appelbaum studies the biology and treatment of leukemias, lymphomas and other blood cancers and sees patients with these disorders. He has made numerous landmark contributions to his field. Notably, he helped develop the renowned program in blood stem cell transplantation at the Fred Hutchinson Cancer Research Center, where he participated in its pioneering work to develop targeted antibody-based cancer therapies. Today, Dr. Appelbaum leads the Adult Leukemia Research Center and the Hematologic Malignancy Program of the Fred Hutchinson/University of Washington Cancer Consortium. These efforts are aimed at enhancing the understanding of these diseases and improving treatments such as blood stem cell transplantation. As Fred Hutch Deputy Director, Dr. Appelbaum leads the implementation of key scientific strategies and partnerships. He also helps to ensure that Fred Hutch advances are shared with the wider community.

Dr. Malech is currently Chief of the Genetic Immunotherapy Section (GIS), and Deputy Chief of the Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The mission of GIS is the development of gene therapy and hematopoietic stem cell transplantation approaches to the treatment of a variety of inherited primary immune deficiencies. Associated with that mission is the diagnosis and treatment of the infections, inflammation, autoimmunity, pulmonary dysfunction, and growth failure that may complicate management of a number of primary immune deficiencies. He has overseen clinical trials of gene therapies that use ex vivo transduction of autologous hematopoietic stem cells, as well as studies of allogeneic HSC transplantation for rare diseases.

Dr. Malech received his medical degree from Yale University in New Haven, Connecticut. He completed clinical residency training at the University of Pennsylvania in Philadelphia, followed by basic research postdoctoral fellowship training at the National Institutes of Health (NIH) in Bethesda, Maryland. After then completing clinical fellowship training in infectious diseases at Yale University, he remained at Yale as assistant and then associate professor. In 1986, he returned to NIH as a senior investigator in NIAID.

Jeffrey V. Ravetch, M.D., Ph.D. is currently the Theresa and Eugene Lang Professor at the
Rockefeller University and Head of the Leonard Wagner Laboratory of Molecular Genetics and
Immunology.

Dr. Ravetch, a native of New York City, earned degrees from Yale University, Cornell Medical
College and The Rockefeller University and pursued postdoctoral studies at the NIH. From 1982
to 1996 Dr. Ravetch was a member of the faculty of Memorial Sloan-Kettering Cancer Center
and Cornell Medical College. His laboratory has focused on the Fc domain of antibodies and
their receptors, establishing their structural and functional diversity and the pre-eminence of FcR
pathways in host defense, inflammation and tolerance. His work has been widely extended into
clinical applications for the treatment of neoplastic, inflammatory and infectious diseases.

Dr. Ravetch has received numerous awards including the William B. Coley Award (2007),
Sanofi-Pasteur Award (2012), Gairdner International Prize (2012), Wolf Prize in Medicine
(2015), Ross Prize in Molecular Medicine (2017) and the Robert Koch award (2018). He is a
member of National Academy of Sciences (2006), the National Academy of Medicine (2007), a
Fellow of the American Academy of Arts and Sciences (2008) and a Fellow of the American
Association for the Advancement of Science (2009).

Ravetch has contributed extensively to the scientific community by serving as a member of the
Scientific Advisory Boards of the Cancer Research Institute, the Irvington Institute for Medical
Research, the Damon Runyon Foundation, the medical advisory board of Gairdner Foundation,
the Sanofi-Pasteur Award Jury and the L’Oreal Women in Science Jury. He has been active in
biotechnology for the last two decades, and currently serves as a consultant or member of the
Scientific Advisory Boards of Harpoon, Kleo, Momenta, Palleon, Portola and Xencor.

Joshua A. Boyce, MD, is the Albert L. Sheffer Professor of Medicine in the Field of Allergic Diseases at Harvard Medical School in Boston, Massachusetts. He is the Chief of the Division of Allergy and Clinical Immunology at the Brigham and Women’s Hospital and the Director of the Jeff and Penny Vinik Center for Allergic Disease Research.

He leads one of the largest and most successful Allergy research and training programs in the United States. He is the principal investigator on several National Institutes of Health grants, including a MERIT award, a U19, and a T32. He is an internationally renowned expert in the role of mast cells and arachidonic acid-derived lipid mediators in the pathogenesis of asthma and innate immunity. He has published over 100 original articles in peer-reviewed scientific journals on the immunologic basis of asthma, and over 50 reviews and textbook chapters.

He has served as the Chairman of the Expert Panel that drafted the 2010 and 2016 versions of the NIH-sponsored guidelines for the Diagnosis and Management of Food Allergy and has served in an advisory capacity to the NIH on several committees. He has been Associate Editor of the Journal of Allergy and Clinical Immunology since 2003. He previously served on the board of directors of the American Board of Allergy and Immunology.

Dr. Boyce has a long track record of accomplishment in the mentoring and education of trainees. More than 20 of his former MD and PhD trainees are full-time faculty at U.S. medical schools, as well as comparable institutions in Europe and Japan. He was the 2020 recipient of the Outstanding Mentor Award from the American Academy of Allergy, Asthma and Immunology, and also received Teacher of the Year awards from the Pediatric Residents at both the University of Massachusetts and the Massachusetts General Hospital and has been recognized three times by Boston Magazine as one of Boston’s best physicians.

Dr. Shizuru is a Professor of Medicine (Blood and Marrow Transplantation) and Pediatrics (Stem Cell Transplantation) at Stanford. She is a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program, and the Institute for Stem Cell Biology and Regenerative Medicine. She has attended on the BMT clinical service since 1997. Dr. Shizuru’s research focuses on understanding the cellular and molecular basis of resistance to engraftment of transplanted allogeneic bone marrow cells and the way in which bone marrow grafts modify immune responses. This research complements her group’s interest in clinical bone marrow transplantation, and aspects of these studies are aimed at solving some of the major problems of bone marrow transplantation, which include graft-vs-host disease and bone marrow engraftment failure. Conventional bone marrow transplantation involves the transfer of heterogeneous populations of cells composed of rare hematopoietic stem cells and differentiated blood cell types. To study these issues, her lab’s approach has been to transplant phenotypically purified cells under defined conditions.

Lawrence (Larry) Schwartz, Distinguished Professor of Medicine, at Virginia Commonwealth University, is a translational research investigator who, with colleagues, has made fundamental discoveries about human mast cells. These include identifying different types of mast cells; and discovering human α-, β-, and α/β-tryptases, characterizing their proteolytic activities, producing an anti-tryptase inhibitor of potential therapeutic utility, and inventing clinically useful tryptase immunoassays that facilitate the diagnosis of systemic mastocytosis (FDA and WHO approved) and of anaphylaxis, the discovery and diagnosis of mast cell activation syndromes and of hereditary alphatryptasemia, and the monitoring of mast cell cytoreductive therapies.

Martin Metz, M.D., is Professor of Dermatology with focus on pruritus research at the Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany. Dr. Metz received his medical education at the Free University of Berlin and the Humboldt University of Berlin. He was trained in dermatology at the King’s College Hospital, London, and at the University of Mainz, and in experimental pathology at Beth Israel Deaconess Medical Centre and Harvard Medical School in Boston (1997–98) and at Stanford University (2004–06) in the USA. Dr. Metz board certified in Dermatology and Allergology, and serves as assistant medical director of the department of dermatology, venerology and allergology as well as principle investigator in the Dermatological Allergology lab at the Charité – Universotätsmedizin Berlin. His main scientific areas of interest are mast cell biology, neuroimmunology, inflammation and innate immunity, the major clinical focus is on pruritus and mast cell mediated diseases.

Dr. Stephen Galli is a globally recognized expert on mast cells and basophils, with a distinguished record as a researcher, educator, and administrative leader. During his tenure as the Chair of the Department of Pathology at Stanford University, spanning from 1999 to 2016, Dr. Galli mentored numerous individuals in research and clinical pathology, while also establishing a career development program for residents across all departments. Prior to joining Stanford, Dr. Galli was a professor of Pathology at Harvard Medical School and served as Director of the Division of Experimental Pathology at Beth Israel Deaconess Medical Center.

Dr. Galli’s research is centered around the roles played by mast cells and basophils in immunological and inflammatory responses, with particular emphasis on their involvement in anaphylaxis, food allergies, and asthma. He has also made significant contributions towards elucidating the function of mast cells in promoting both innate and acquired, IgE-enhanced, host defense against venoms and certain bacteria. Furthermore, his research has led to the discovery that mast cells play a crucial role in maintaining homeostasis and ensuring survival.

Dr. Galli earned his BA in Biology from Harvard College, followed by a BMS from Dartmouth Medical School and an MD from Harvard Medical School.